Supreme Court Criticizes NPPA for Exorbitant Drug Prices: MRP Rs 11,000 Injection Sold for Rs 1.3 Lakh

1At a glance

The Supreme Court of India has sharply criticized the National Pharmaceutical Pricing Authority (NPPA) and the government for failing to regulate exorbitant trade margins on essential drugs. Highlighting a case where a cancer injection costing Rs 11,000 was sold for Rs 1.3 lakh, the Court questioned the efficacy of existing price control mechanisms and called the current system 'loot and robbery'.

Judicial Scrutiny
The Supreme Court questioned the government's price control policy and termed the huge MRP-PTR gap as 'loot and robbery'.
Price Disparity
A cancer injection with a base price of Rs 11,000 was being sold to patients at Rs 1.3 lakh, highlighting massive trade margins.
Regulatory Action
NPPA capped the trade margin on cancer drugs at 30% of MRP, but the Court found this measure inadequate.

2Facts to remember

Tap a card to see the answer. Try to recall it first.

3Detailed analysis

Context / Background

India regulates the prices of essential medicines under the Drugs (Prices Control) Order (DPCO) through the National Pharmaceutical Pricing Authority (NPPA). The system aims to balance drug affordability with industry viability. However, the Supreme Court's intervention stems from persistent complaints about huge differences between the price to retailer (PTR) and the maximum retail price (MRP), which burdens patients, especially for critical treatments like cancer.

Core Analysis & Implications

The Court's criticism exposes a fundamental flaw in the regulatory framework. While the government argues that trade margins are needed to ensure drug distribution to remote areas, the Court highlighted that margins of over 1000% (as in the Rs 11,000 to Rs 1.3 lakh case) cannot be justified. The recent 30% trade margin cap on cancer drugs, though a step, is seen as reactive and insufficient. The case underscores the conflict between a free-market approach in healthcare and the state's obligation under Article 21 (Right to Life) to ensure affordable medical care.

Future Outlook / Way Forward

The Supreme Court has reserved its judgment, which may direct the government to expand the list of drugs under price control and strengthen the NPPA's enforcement powers. A likely outcome is a mandate for more transparent pricing mechanisms and stricter audits of hospital and retailer margins. This could lead to amendments in the DPCO or new legislation to prevent profiteering in essential medicines.

4Background GK

Textbook concepts you need to understand this news

National Pharmaceutical Pricing Authority (NPPA): An independent body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, responsible for controlling the prices of essential drugs in India under the Drugs (Prices Control) Order (DPCO).
Drugs (Prices Control) Order (DPCO): An order issued by the Government of India under the Essential Commodities Act, 1955, to regulate the prices of essential life-saving medicines.
Trade Margin: The difference between the price at which the manufacturer sells to the retailer (PTR) and the maximum retail price (MRP) at which it is sold to the consumer. It covers retailer profit, distribution costs, and taxes.

5How exams will ask this

Data: Trade margin cap on cancer drugs is 30% of MRP (October 2026).
Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under Dept. of Pharmaceuticals.
Legal Point: Drug price control is enforced under the Drugs (Prices Control) Order (DPCO).

Don't make this mistake!

They may ask which ministry NPPA falls under (Chemicals and Fertilizers, NOT Health) or confuse the trade margin percentage (e.g., 50% vs 30%). Another trap is asking about the constitutional article invoked (Article 21 - Right to Life) in the context of affordable healthcare.

Write these in mains answers

Judicial activism in public healthConflict between market economics and welfare stateRegulatory failure and patient vulnerability

6Practice questions

Pick an answer, then read the explanation.

Q1Hard
Consider the following statements regarding the recent Supreme Court hearing on drug prices:
1. 1.The Court criticized the National Pharmaceutical Pricing Authority (NPPA) for being 'completely passive'.
2. 2.The government has capped the trade margin on all essential drugs at 30% of the Maximum Retail Price.
3. 3.The Court termed the existing system of high drug price margins as 'loot and robbery'.
Which of the statements given above is/are correct?
Explanation: Statement 1 is correct as the article states the Court observed that NPPA appears 'completely passive'. Statement 2 is incorrect because the 30% trade margin cap, as per the article, applies specifically to cancer drugs, not all essential drugs. Statement 3 is correct as the Court described the system as 'loot and robbery'.
Q2Medium
According to the news, what is the trade margin cap set by the government for cancer drugs?
Explanation: The article clearly states that following Supreme Court criticism, the government decided to cap the trade margin on cancer drugs at 30% of the Maximum Retail Price (MRP). This decision was taken in NPPA's 151st meeting on October 8, 2026.
Q3Medium
What was the primary reason for the Supreme Court's criticism of the government's argument that drug prices in India are lower than in many countries?
Explanation: As per the article, when the government's lawyer argued that drug prices in India are lower than in many countries, the Court questioned whether such a 'capitalist approach' should be adopted when the issue concerns patients and their lives. This highlights the Court's welfare-oriented perspective over a purely market-based argument.

7All sources

Original28 October 2026 · Read story